New Technology for Vaccines and Vaccine-Preventable Diseases

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue on New Technologies for Vaccines and Vaccine-Preventable Diseases. The development of vaccines has long been a cornerstone of global public health, saving millions of lives by preventing infectious diseases. With the advent of new technologies, the landscape of vaccine development has dramatically transformed. Cutting-edge platforms like mRNA vaccines, viral vector-based vaccines, and AI-driven tools are revolutionizing the speed, efficacy, and accessibility of vaccines. As infectious diseases continue to evolve and new pathogens emerge, the need for innovative vaccine solutions has never been more pressing. Advances in vaccine technologies not only promise to address longstanding health challenges but also provide new strategies for preventing future pandemics. The integration of artificial intelligence, big data, and other digital technologies into vaccine research opens up unprecedented opportunities for understanding epidemiology, predicting disease outbreaks, and accelerating vaccine design. This Special Issue will showcase the latest developments in the field, highlighting the critical role these innovations play in tackling both current and future global health threats.

In this Special Issue, original research articles, reviews, meta-analyses, commentaries, and short communications are welcome. Research areas may include (but are not limited to) the following:

• Innovative vaccine technologies: new vaccine platforms and vaccine delivery systems; vaccine efficacy and safety of new vaccines; and vaccines for newly recognized or re-emerging infectious diseases.
• Vaccine distribution and accessibility: improving global vaccine access.
• Immunology of vaccine responses: cellular and humoral immunity in new vaccines.
• Artificial intelligence and big data: applications in vaccine-preventable disease epidemiology, disease prediction, vaccine development, and understanding vaccine-induced immunity.

We look forward to receiving your contributions that push the boundaries of vaccine science and technology.

Dr. Jue Liu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.